Progenika Biopharma SA creates a subsidiary in the UK
Progenika Ltd will provide a diagnostic service based on the unique Sendagene(TM) platform for the diagnosis of genetically complex diseases. Dr Laureano Simon, company founder and CEO, underlined the enormous potential of the Sendagene(TM) technology for the early diagnosis of potentially debilitating conditions allowing doctors to treat and control important diseases suffered by their patients such as Familial Hypercholesterolaemia and Inflammatory Bowel Disease. The creation of Progenika Biopharma Ltd brings the possibility of individualized medicine one step closer to reality he said in a statement today.
Most read news
Topics
Organizations
Other news from the department manufacturing
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.